Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Idan Elmelech is COO & Principal Financial Ofcr at Bridgebio Oncology Therapeutics. OQRO lists 3 transactions filed with the SEC under this name, the latest on Oct 6, 2026, each linked to the official Form 4.
COO & Principal Financial Ofcr
Disclosures on record
3
Companies involved
1
Bridgebio Oncology TherapeuticsBBOT
3 disclosures · May 2026 – Oct 2026
Oct 1, 2026343disclosed Oct 6
DetailsOfficial recordJul 1, 2026343disclosed Jul 7
DetailsMay 10, 2026758Kdisclosed May 13
DetailsOfficial recordAs of the latest filing on , Idan Elmelech reported holding 14,152 shares of Bridgebio Oncology Therapeutics (BBOT), worth about $26K at the last close of $2 (Nov 18, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Bridgebio Oncology Therapeutics BBOT | 14,152 | 14K direct | $2 | $26K | Oct 1, 2026 |
Is this Idan Elmelech’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Oct 1, 2026, Idan Elmelech reported holding 14,152 shares of Bridgebio Oncology Therapeutics (BBOT). At the last close of $2 on Nov 18, 2026, that is about $26K. This is the stake disclosed in filings, not a net worth.
No public filing gives Idan Elmelech's net worth. What SEC Form 4 shows is the stock stake: 14,152 shares of Bridgebio Oncology Therapeutics (BBOT), about $26K at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.